Masimo reports preliminary Q4 2024 revenue ~$601M, healthcare up 9%; issues FY 2025 guidance

MASIMO CORP

2024-FY EPS reported -$5.72 revenue$2,094,400,000

Q4 2024 consolidated revenue ~$601M (+9% YoY); healthcare revenue ~$368M (+8% reported, +9% constant currency).
FY 2024 consolidated revenue ~$2,094M (+2%); healthcare $1,395M (+9%); non-healthcare $699M (-10%).
Non-GAAP EPS FY 2024 expected >$4.10 (high end of prior guidance range).
FY 2025 healthcare revenue guidance $1,500M-$1,530M (8-11% constant currency growth); non-GAAP EPS $4.90-$5.10.
Q4 shipments of noninvasive technology boards/instruments ~65K units.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.